CEO Robert Parkinson

New York, May 25th (TradersHuddle.com) - Baxter International, Inc. (NYSE:BAX) closed the trading session at $52.25, near its 200 day moving average set at $54.45. Baxter's stock action is below this level, which makes the stock difficult to be bought, as ...  

Analyzing the price chart for Baxter International (NYSE:BAX) has revealed a potential bullish harami candle pattern. Today's real body is within yesterday's body and may imply that traders and investors believe that the recent move lower is exhausted.  

Baxter appealed an obviousness finding from a re-examination proceeding.  The CAFC noted Because the Board did not err in determining that those claims would have been obvious to one of ordinary skill in the art, we affirm.From the decision:  First, as recounted above, the Board expressly considered our decision in Fresenius. More fun- damentally, the PTO in reexamination proceedings and the court system in patent infringement actions “take...  

Baxter International Inc.’s more than $1 billion Covington, Ga., plant is a bet on the long-term growth of the company’s plasma-based specialty therapeutics business, company executives said in a conference call with analysts Thursday. “The announcement this morning is an expression that represents our confidence in the long-term global growth of the plasma protein business,” CEO Robert Parkinson told analysts. “Over half the world’s...  

Baxter International Inc. increased its top executive’s total compensation package 22 percent to about $14.1 million in 2011, according to the company’s annual proxy filing with the Securities and Exchange Commission. Baxter Chairman and CEO Robert L. Parkinson Jr.’s total comp last year included a $1.4 million salary (up 2.8 percent), $5.1 million in stock awards (up 14.7 percent), $3.4 million in option awards (up 27 percent), $2.9 million...  

PARIS--(BUSINESS WIRE)-- Baxter International Inc. (NYSE: BAX) today announced results from two large, international multicenter trials demonstrating that a low glucose peritoneal dialysis (PD) regimen favorably impacted metabolic measures important for ...  

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) today announced the approval of ADVATE [Recombinant Human Coagulation Factor VIII for injection] for the control and prophylaxis of bleeding episodes in individuals with hemophilia A (congenital factor VIII deficiency) in China by the State Food and Drug Administration (SFDA). It is estimated that more than 50,000 people in China...  

Baxter International Inc. (NYSE: BAX) today announced results from two large, international multicenter trials demonstrating that a low glucose peritoneal dialysis (PD) regimen favorably impacted metabolic measures important for end-stage renal ...  

(RTTNews) - Baxter International Inc. (BAX: News ) said results from two large, international multicenter trials demonstrated that a low glucose peritoneal dialysis, or PD, regimen favorably impacted metabolic measures important for end-stage renal disease ...  

Baxter International Inc. (NYSE ... ADVATE is a full-length (derived from the complete FVIII gene) recombinant FVIII product that is processed without any blood-based additives. Because no blood derived components are added at any stage of the ...  

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) announced today it has exercised its option and completed the purchase of SIGMA International General Medical Apparatus, LLC., a privately held company based in Medina, New York, by acquiring the remaining 60 percent of the company for a cash payment of approximately $90 million. In 2009, Baxter entered into an agreement with SIGMA...  

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) today announced the presentation of Phase III clinical data evaluating the safety and efficacy of GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] for the treatment of multifocal motor neuropathy (MMN). The data were presented during a Clinical Trials Forum at the 64th annual meeting of the American Academy of Neurology ...  

DEERFIELD, Ill., Apr 19, 2012 (BUSINESS WIRE) -- Baxter International Inc. BAX -0.46% , a global leader in biologic medical therapies, today announced it will build a new state-of-the-art manufacturing facility in Georgia to support growth of its plasma-based treatments. These therapies include treatments for immune disorders, trauma and other critical conditions.Baxter expects capital...  

DEERFIELD, Ill. & SAN DIEGO--(BUSINESS WIRE)-- Baxter International Inc. (NYSE:BAX - News) and Halozyme Therapeutics, Inc. (NASDAQ:HALO - News) today announced that the U.S. Food and Drug Administration (FDA) is requesting additional information to complete its review of the HyQ Biologics License Application (BLA).Baxter and Halozyme will work closely together to develop studies to provide...  

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International (NYSE:BAX), will host a quarterly conference call to discuss its first quarter 2012 financial results on Thursday, April 19, 2012, at 8:30 a.m. Eastern Time (7:30 a.m. Central Time). To access the call, please dial 866-818-1223 (domestic) or 703-639-1376 (international). Please dial into the call at least ten minutes prior to the start of the call...  

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International (NYSE:BAX), will host a quarterly conference call to discuss its first quarter 2012 financial results on Thursday, April 19, 2012, at 8:30 a.m. Eastern Time (7:30 a.m. Central Time). To access the call, please dial 866-818-1223 (domestic) or 703-639-1376 (international). Please dial into the call at least ten minutes prior to the start of the call for the operator to connect you. This call...  

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE: BAX) announced today that it will present at Deutsche Bank Securities, Inc. 37th Annual Healthcare Conference on Wednesday, May 9, 2012, at 9:20 a.m. ET. The live webcast of Baxter’s presentation can be accessed from the Baxter corporate website at www.baxter.com and will be available for replay through June 8, 2012. Baxter International Inc. develops, manufactures and markets...  

DEERFIELD, Ill. and SAN DIEGO, Calif., April 16, 2012 /PRNewswire/ -- Baxter International Inc. (NYSE: BAX) and Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) is requesting additional information to complete its review of the...  

New York, May 1st (TradersHuddle.com) - Baxter International, Inc. (NYSE:BAX) closed the trading day at $55.41, near its 50 day and 200 day moving averages set at $57.82 and $54.84 respectively. Baxter's price action placed the stock above the 200 day ...  

as part of its efforts to expand its plasma-based treatments for immune disorders, trauma and other critical conditions ... Safety Data Evaluating GAMMAGARD LIQUID for Multifo.. 04/26 DJ Baxter Completes Purchase Of SIGMA International For $90 Million ...  

TERRE HAUTE — Rose-Hulman Institute of Technology alumna Elizabeth M ... Baxter Healthcare is a subsidiary of Illinois-based Baxter International Inc., a worldwide leader in patient care products. Hagerman most recently led the global integration ...  

The acquisition of SIGMA builds upon Baxter's long-standing leadership in IV medication and fluid delivery and demonstrates our commitment to patient safety as a global, leading provider of smart infusion systems,'' said Robert M. Davis, president of ...  

In trading on Thursday, shares of Baxter International Inc. (NYSE: BAX) crossed above their 200 day moving average of $54.62, changing hands as high as $54.97 per share. Baxter International Inc. shares are currently trading up about 0.4% on the day.  

Baxter International is a pharmaceuticals company that is building a new plant in Georgia.  The plant is based in Illinois and is a maker of vaccines, medical devices and treatments for blood disorders.  The company will invest $1 billion over the ...  

In trading on Thursday, shares of Baxter International Inc. (NYSE: BAX) crossed above their 200 day moving average of $54.62, changing hands as high as $54.97 per share. Baxter International Inc. shares are currently trading up about 0.4% on the day. The chart below shows the one year performance of BAX shares, versus its 200 ...  

Baxter International Inc. (NYSE:BAX - News) today announced the approval of ADVATE [Recombinant Human Coagulation Factor VIII for injection] for the control and prophylaxis of bleeding episodes in individuals with hemophilia A (congenital factor ...  

New York, April 17th (TradersHuddle.com) - Baxter International, Inc. (NYSE:BAX) closed the trading session at $54.10, near its 200 day moving average set at $55.13. Baxter's stock action is below this level, which makes the stock difficult to be bought ...  

DEERFIELD, Ill. — Drug and medical device maker Baxter International Inc. said Thursday its profit grew 3 percent in the first quarter on better sales of hemophilia and immune disease treatments, anesthetics, and other products. Baxter said ...  

Inc. (Synovis) acquisition, which was completed during the quarter, and solid growth in select specialty plasma-based therapies and vaccines. Medical Products sales of more than $1.9 billion increased 3 percent (with foreign currency having no impact on ...  

For the quarter ended March 31 (Q1), Baxter International beat expectations on revenues and met expectations on earnings per share. Compared to the prior-year quarter, both revenue and GAAP earnings per share grew. Gross margin and operating ...  

For the quarter ended March 31 (Q1), Baxter International beat expectations on revenues and met expectations on earnings per share. Compared to the prior-year quarter, both revenue and GAAP earnings per share grew. Gross margin and operating ...  

New York, April 13th (TradersHuddle.com) - Baxter International, Inc. (NYSE:BAX) closed the trading day at $58.71, near its 50 day moving average that is set at $58.29. Baxter's price action is just above this important support level, providing a trading ...  

“Baxter’s decision to come to Georgia marks a new era in the ... in time, its offshoots may deliver. Peter Keller spent eight years carving his hole in the side of the mountain, camouflaging the rugged underground bunker with ferns and sticks and ...  

NEW YORK (AVAFIN) -- Baxter International witnessed an unusual number of call and put contracts exchanging hands during the busy trading session versus the average 10-day contract volume . There were 0.8 call contracts traded for every put ...  

Add Baxter International  to My Watchlist. The Steve Jobs Betrayal You may already know that in the final year of his life, Jobs revealed a stunning betrayal — and told his biographer, "I will spend my last dying breath... and every penny of ...  

Baxter International Inc. (BAX) will build a manufacturing facility ... creates more than 1,500 full-time positions in Georgia and a total of roughly 2,000 jobs across multiple U.S. locations. The company has a total of about 48,500 employees.  

To have a company of Baxter's stature decide to come to Georgia, underscores the state's reputation as a growing life sciences hub, said David Dodd, who founded Atlanta-based Serologicals Corp. and was a former CEO at Solvay Pharmaceuticals Inc. Companies ...  

Commercial production is scheduled to begin in 2018, with the new plasma fractionation facility adding up to three million ... Georgia for maintaining a long-term pipeline of highly skilled employees who are well-trained in bio-manufacturing ...  

New York, April 3rd (TradersHuddle.com) - Baxter International, Inc. (NYSE:BAX) closed the trading day at $60.25, near its 50 day moving average that is set at $57.70. Baxter's price action is just above this important support level, providing a trading ...  

DEERFIELD, Ill.--(BUSINESS WIRE)--Mar 22, 2012 - Baxter International (NYSE:BAX), will host a quarterly conference call to discuss its first quarter 2012 financial results on Thursday, April 19, 2012, at 8:30 a.m. Eastern Time (7:30 a.m. Central Time).  

Below, we'll revisit how Baxter International does on our 10-point scale. The right stocks for retirees With decades to go before you need to tap your investments, you can take greater risks, weighing the chance of big losses against the ...  

Baxter International Inc. announced it will build a biopharmaceutical plant southeast of Atlanta to support global growth of its plasma-based treatments for immune disorders, trauma and other conditions. Baxter expects capital investments at the Covington ...  

will soon be home to Baxter International Inc.’s Baxter International Inc. Latest from The Business Journals Follow this company (NYSE: BAX) new $1 billion plasma-based treatments manufacturing plant. The facility will create more than 1,500 ...  

Over at Georgia Report, Tom Crawford is reporting that the incentive package that bio-tech firm Baxter International received to build a manufacturing facility in east Georgia could exceed $126.5 million: That amount is about 62 percent higher ...  

The Atlanta Journal-Constitution ( http://bit.ly/IFgIwJ) reports that Baxter International Inc. could receive the incentives from state and local governments for the bio-pharmaceutical manufacturing facility. Gov. Nathan Deal announced last week that ...  

Baxter International Inc. (BAX) has completed its purchase of the remaining 60% of SIGMA International General Medical Apparatus Llc., a private company, for around $90 million in cash. SIGMA develops and manufactures products like the Spectrum ...  

Baxter International Inc. (NYSE:BAX - News) announced today it has exercised its option and completed the purchase of SIGMA International General Medical Apparatus, LLC., a privately held company based in Medina, New York, by acquiring the ...  

Baxter International Inc. (NYSE:BAX - News), a global leader in biologic medical therapies, today announced it will build a new state-of-the-art manufacturing facility in Georgia to support growth of its plasma-based treatments. These therapies ...  

Baxter International Inc.'s (NYSE:BAX) first-quarter earnings rose 3.2% as the medical-products company saw growth across its core segments, driven by strong demand for its hemophilia and immuno-deficiency treatments, as well as its anesthesia products.  

Hagerman has a wealth of experience in business development ... Baxter Healthcare is a subsidiary of Illinois-based Baxter International Inc., a worldwide leader patient care products. Hagerman most recently led the global integration of ...  

Baxter International Inc. (NYSE:BAX) today announced the presentation of Phase III clinical data evaluating the safety and efficacy of GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] for the treatment of multifocal motor neuropathy (MMN).  

* Sales up 3 pct to $3.4 bln, up 4 pct excluding forex April 19 (Reuters) - Baxter International Inc reported better-than-expected first-quarter earnings on Thursday, helped by an acquisition and strong demand for its treatments for hemophilia ...  

Baxter International on Thursday purchased SIGMA International General Medical Apparatus, a privately-held New York firm that manufacturers medical pumps for delivering fluids and medications to patients. Baxter, based in Deerfield, had ...  

My AJC colleague Chris Quinn reports that the price of luring Baxter International to Georgia could be more than double last week’s estimate: Incentives for luring a new pharmaceutical manufacturing plant and its 1,500 promised jobs to a ...  

Seeking to meet growing demand for its plasma-based treatments for immune disorders, trauma and other conditions, Baxter International Inc. said Thursday that it plans to spend up to $1 billion over the next five years to open a new production ...  

NEW YORK - Baxter International Inc. and Halozyme Therapeutics Inc. said Monday that regulators will take more time to review their immune disease drug HyQ, sending Halozyme shares plunging in midday trading. The companies said the Food and Drug ...  

Shares of Baxter International Inc.fell nearly 7 percent Monday after the company said the U.S. Food and Drug Administrationhad requested more data on the long-term use of a new treatment for certain types of immune system disorders. The FDA's ...  

Less than two months after North Carolina lost a massive Caterpillar plant to Georgia, the Tar Heel state finds itself on the losing side again. And this time it was Granville County. Healthcare conglomerate Baxter International Inc. plans to ...  

Baxter International Inc. and Halozyme Therapeutics Inc. said U.S. health regulators requested more data to complete their review of HyQ Biologics. HyQ is an experimental, combination product that includes Immune Globulin and Recombinant Human ...  

Baxter International Inc. (NYSE:BAX - News) today posted solid first quarter financial results which exceeded the company’s previously issued revenue and earnings ... 450 patients across 50 sites in the United States. CMI is one of the most ...  

DEERFIELD — Baxter International Inc., said Thursday the company plans to create more than 200 new jobs at its Round Lake facility as part of the company’s expansion of plasma-based treatments. At the same time, Baxter said it will build a ...  

Baxter International To Presnet At Deutsche Bank Conference; Webcast At 9:20 AM  

based Baxter International Inc. reflect its "strong" business risk ... despite the significant distribution of cash (via dividends and common stock repurchases) to shareholders.  

Shares of some top pharmaceuticals companies are mixed at 10 a.m.:Baxter International Inc. fell $.15 or .3 percent, to $59.25.Bristol-Myers Squibb Co. fell $.12 or .4 percent, to $33.00.Hospira fell $.23 ...  

Shares of some top pharmaceuticals companies are mixed at 1 p.m.:Baxter International Inc. fell $.60 or 1.1 percent, to $51.61.Bristol-Myers Squibb Co. rose $.08 or .2 percent, to $32.83.Hospira fell $.35 ...  

Baxter International Inc. plasma-based treatments. These therapies include treatments for immune disorders, trauma and other critical conditions.  

Baxter International Inc. announced today that it will present at the Bank of America Merrill Lynch 2012 Healthcare Conference on Wednesday, May 16, 2012, at 11:20 a.m.